Key facts
- It has raised $32.0M across 2 recorded rounds; the latest was Later Stage VC (Series A) ($25.0M) in Feb 2025.
- Notable investors include Metaplanet Holdings, Lux Capital, VSquared Ventures, Nordic Mentor Network For Entrepreneurship, GRIDS Capital — 7 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Atrandi Biosciences
Funding rounds
2 roundsAbout Atrandi Biosciences
Developer of life sciences research tools designed to enable high-throughput single-cell analysis using compartmentalization technology, operating in the biotechnology research tools industry. The company offers a patented semi-permeable capsule platform that isolates individual cells in discrete, permeable compartments while allowing bulk biochemical reactions, supporting microbial and eukaryotic genomics and single-cell multiomics workflows, enabling researchers to conduct scalable single-cell experiments while preserving single-cell resolution.
- Industry
- Discovery Tools (Healthcare)
- Sector
- Healthcare
- HQ
- Vilnius, Lithuania
- Founded
- 2016
- Employees
- 78
- Website
- atrandi.com/
- Ownership
- Privately Held (backing)
Atrandi Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Atrandi Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Atrandi Biosciences in its N-PORT filings yet. We sweep new filings monthly.